Company Overview of PanGenex Corporation
As of April 8, 2008, PanGenex Corporation was acquired by Calgenex Corporation, in a reverse merger transaction. PanGenex Corp. develops and markets nutraceuticals and topical over the counter (OTC) drugs and personal care products. Its products include Calci-CLEAR, a program that helps cleanse bodies of calcium crystals; Omeganol, a supplement that combines the triglyceride-lowering properties of omega 3s with the cholesterol balancing activity of tocotrienols; and Dermallve, a lotion that relieves symptoms of chronic skin diseases. The company caters to nutraceutical and cardiovascular health industries. PanGenex is based in Tampa, Florida.
9950 Princess Palm Avenue
Tampa, FL 33619
Key Executives for PanGenex Corporation
PanGenex Corporation does not have any Key Executives recorded.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PanGenex Corporation, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.